3-CMC
3-CMC is a synthetic stimulant of the substituted cathinone class, first detected in 2014.1 Structurally related to other methcathinone derivatives such as 3-MMC and 4-CMC, it is a halogenated cathinone1 that produces stimulating and possibly entactogenic effects often compared to those of mephedrone and, to a lesser extent, MDMA and cocaine. It has been primarily sold online as a designer drug in European markets.2
Dosage & Duration
Dosage
Dosage information for this substance remains preliminary; users should exercise caution and conduct additional research before use.
Duration
Subjective Effects
3-CMC produces a classic entactogenic stimulant experience frequently compared to mephedrone and 3-MMC, with lesser resemblance to MDMA and cocaine. The experience centers on euphoria, mood lift, increased confidence, and a strong pull toward socializing and talking. Relative to 3-MMC, users consistently describe the effects as weaker and shorter-lasting, which contributes to a pattern of compulsive redosing among some users.
Physical
The body experience is one of energetic stimulation with increased energy and alertness, decreased need for sleep, and suppressed appetite. Sweating, elevated body temperature, dry mouth, jaw tension, increased heart rate, and elevated blood pressure accompany the stimulation, and sleep patterns are often disturbed for some time after use.
Cognitive
The headspace is euphoric, confident, and highly social, with a marked drive toward conversation and excessive talking. Negative states including anxiety, moodiness, irritability, and aggression can emerge, particularly during the offset or with heavy use, and episodes of psychosis have been associated with cathinone exposure.
Emotional
Enhancements
Visual
Visual effects are not a characteristic feature of the experience; hallucinations are reported primarily as an adverse outcome of heavy use.
Auditory
Pharmacology
Pharmacodynamics
3-CMC acts as both a monoamine releasing agent and reuptake inhibitor at the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT).2 In rat brain cell studies, it showed comparable interaction with DAT and NET relative to mephedrone, while interacting significantly less with SERT.3 This produces a pharmacological profile that favors dopamine release in proportion to serotonin release.2
Pharmacokinetics
The metabolism of 3-CMC in humans has not been extensively studied.2 Based on the metabolism of structurally similar cathinones, it is expected to undergo hepatic metabolism through oxidation, reduction, hydrolysis, and conjugation reactions. A proposed biotransformation pathway predicts the formation of several metabolites including dihydro-3-CMC, N-desmethyl-3-CMC, and N-desmethyl-dihydro-3-CMC.4
Interactions
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Cathinone stimulants, Dopaminergic stimulants
Harm Potential
History & Culture
3-CMC first appeared in 2014, emerging as part of the broader wave of synthetic cathinones entering the European designer drug market during this period.8 The substance was primarily sold through online vendors, with initial distribution concentrated in Germany,…
Legality
International
European Commission control measures (March 2022)9
By Country
References
Source Pages
Citations
- Agnieszka Romańczuk, Sebastian Rojek, Kamil Synowiec, Martyna Maciów-Głąb, Karol Kula, & Ewa Rzepecka-Woźniak. (2023). The Stability of Synthetic Cathinones and the Study of Potential Intake Biomarkers in the Biological Material from a Case of 3-CMC Poisoning. 47(5), 470-480. https://doi.org/10.1093/jat/bkad01012
- Report on the risk assessment of 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2022). https://www.euda.europa.eu/system/files/publications/14509/Report%20on%20the%20risk%20assessment%20of%203-CMC.pdf12345678
- Bruce E Blough, Ann M Decker, Antonio Landavazo, Ojas A Namjoshi, John S Partilla, Michael H Baumann, & Richard B Rothman. (March 2019). The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes. Psychopharmacology, 236(3), 915–924. https://doi.org/10.1007/s00213-018-5063-91
- Diletta Berardinelli, Omayema Taoussi, Gloria Daziani, Francesco Tavoletta, Giovanna Ricci, Livio P Tronconi, Piotr Adamowicz, Francesco P Busardò, & Jeremy Carlier. (June 2024). 3-CMC, 4-CMC, and 4-BMC Human Metabolic Profiling: New Major Pathways to Document Consumption of Methcathinone Analogues?. The AAPS Journal, 26(4), 70. https://doi.org/10.1208/s12248-024-00940-81
- Michael Capriola. (2013). Synthetic cathinone abuse. Clinical Pharmacology, 5, 109–115. https://doi.org/10.2147/cpaa.s4283212
- Ana Patrícia Gomes, Raquel Ferro, Daniela Pinto, Joana Silva, Celso Alves, Rita Pacheco, & Helena Gaspar. (April 2025). Synthesis, Characterization, and Biological Effects of Chloro-Cathinones: Toxicity and Potential Neurological Impact. International Journal of Molecular Sciences, 26(8), 3540. https://doi.org/10.3390/ijms260835401
- Jakub Wojcieszak, Katarzyna Kuczyńska, & Jolanta B Zawilska. (August 2020). Four Synthetic Cathinones: 3-Chloromethcathinone, 4-Chloromethcathinone, 4-Fluoro-α-Pyrrolidinopentiophenone, and 4-Methoxy-α-Pyrrolidinopentiophenone Produce Changes in the Spontaneous Locomotor Activity and Motor Performance in Mice with Varied Profiles. Neurotoxicity Research, 38(2), 536–551. https://doi.org/10.1007/s12640-020-00227-81
- EMCDDA. (2022). EMCDDA initial report on the new psychoactive substance 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC). https://www.euda.europa.eu/publications/initial-reports/initial-report-3-cmc_en123456
- European Commission. (2022). Commission Delegated Directive (EU) 2022/1326 of 18 March 2022 amending the Annex to Council Framework Decision 2004/757/JHA as regards the inclusion of new psychoactive substances in the definition of 'drug'. Official Journal of the European Union. https://eur-lex.europa.eu/eli/dir_del/2022/1326/oj/eng/pdf1
- Decreto 560/2019, Anexo I (sustituido por Decreto 122/2026). argentina.gob.ar (n.d.). https://www.argentina.gob.ar/normativa/nacional/decreto-560-2019-326675/actualizacion1
- Decreto 560/2019, Anexo I (sustituido por Decreto 122/2026). argentina.gob.ar (n.d.). https://www.argentina.gob.ar/normativa/nacional/decreto-122-2026-423520/texto1
- Decreto 560/2019, Anexo I (sustituido por Decreto 122/2026). argentina.gob.ar (n.d.). https://www.argentina.gob.ar/normativa/423520_dec122_jpg/archivo1
- Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026, Schedule 9. legislation.gov.au (n.d.). https://www.legislation.gov.au/F2026L006331
- Government Resolution No. 681 of 30 June 1998, Schedule I (current consolidated text). publications.europa.eu (n.d.). https://publications.europa.eu/resource/celex/32022L132612
- Council Framework Decision 2004/757/JHA, Annex point 21, as amended by Commission Delegated Directive (EU) 2022/1326. publications.europa.eu (n.d.). https://publications.europa.eu/resource/celex/02004F0757-202601121
- Valtioneuvoston asetus huumausaineina pidettävistä aineista, valmisteista ja kasveista (543/2008). finlex.fi (n.d.). https://www.finlex.fi/fi/lainsaadanto/2008/5431
- Décision du 05/08/2024 modifiant l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants. ansm.sante.fr (n.d.). https://ansm.sante.fr/actualites/decision-du-05-08-2024-portant-modification-de-la-liste-des-substances-classees-comme-stupefiants1
- Neue-psychoaktive-Stoffe-Gesetz (NpSG), Anlage 1 Nr. 1 and § 3. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/BJNR261510016.html1
- Neue-psychoaktive-Stoffe-Gesetz (NpSG), Anlage 1 Nr. 1 and § 3. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/__3.html1
- Narcotics and Psychotropics Control Law. ncd.mhlw.go.jp (n.d.). https://www.ncd.mhlw.go.jp/dl_data/keitai/cotrolled_substances_list20241212%20.pdf1
- Opiumwet. wetten.overheid.nl (n.d.). https://wetten.overheid.nl/BWBR0001941/1
- Forskrift om narkotika (FOR-2013-02-14-199), narkotikalisten. lovdata.no (n.d.). https://lovdata.no/dokument/SF/forskrift/2013-02-14-1991
- Dangerous Drugs Board Regulation No. 2, Series of 2025. ddb.gov.ph (n.d.). https://ddb.gov.ph/wp-content/uploads/2025/04/2025-BOARD-REGULATION-NO.-2.pdf1
- Rozporządzenie Ministra Zdrowia z 30 kwietnia 2025 r. zmieniające rozporządzenie w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych (Dz. U. 2025 poz. 598). api.sejm.gov.pl (n.d.). https://api.sejm.gov.pl/eli/acts/DU/2025/598/text.pdf1
- Rozporządzenie Ministra Zdrowia z 30 kwietnia 2025 r. zmieniające rozporządzenie w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych (Dz. U. 2025 poz. 598). eli.gov.pl (n.d.). https://eli.gov.pl/api/acts/DU/2023/1939/text.html1
- Government Resolution No. 681 of 30 June 1998, Schedule I (current consolidated text). pravo.gov.ru (n.d.). http://pravo.gov.ru/proxy/ips/?docbody=&nd=1020539281
- Misuse of Drugs Act 1973, First Schedule, Class A drugs, paragraph 16(8AC). sso.agc.gov.sg (n.d.). https://sso.agc.gov.sg/Act/MDA1973?ProvIds=Sc1-1
- Enforcement Decree of the Narcotics Control Act (마약류 관리에 관한 법률 시행령), Appendix 3. law.go.kr (n.d.). https://www.law.go.kr/LSW/flDownload.do?bylClsCd=110201&flSeq=1596003171
- Orden SND/884/2024, de 14 de agosto, que modifica el anexo 1 del Real Decreto 2829/1977. boe.es (n.d.). https://www.boe.es/buscar/doc.php?id=BOE-A-2024-171521
- Orden SND/884/2024, de 14 de agosto, que modifica el anexo 1 del Real Decreto 2829/1977. boe.es (n.d.). https://www.boe.es/buscar/act.php?id=BOE-A-1977-271601
- Förordning (1992:1554) om kontroll av narkotika, bilaga 1; Narkotikastrafflag (1968:64), 1 §. rkrattsbaser.gov.se (n.d.). http://rkrattsbaser.gov.se/sfst?bet=1992:15541
- Förordning (1992:1554) om kontroll av narkotika, bilaga 1; Narkotikastrafflag (1968:64), 1 §. rkrattsbaser.gov.se (n.d.). http://rkrattsbaser.gov.se/sfst?bet=1968:641
- Betäubungsmittelverzeichnisverordnung (BetmVV-EDI), Anhang 6, Verzeichnis e, Nr. 1. fedlex.data.admin.ch (n.d.). https://fedlex.data.admin.ch/filestore/fedlex.data.admin.ch/eli/cc/2011/363/20241105/de/html/fedlex-data-admin-ch-eli-cc-2011-363-20241105-de-html-2.html1
- Ministerial Notification Re: Specifying Names of Category 1 Narcotics (No. 4), B.E. 2568 (2025). nctsearch.fda.moph.go.th (n.d.). https://nctsearch.fda.moph.go.th/NARCOTIC_MOPH/?page=NARCOTIC_DRUG1
- Resolution of the Cabinet of Ministers of Ukraine No. 770 of 6 May 2000, On Approval of the List of Narcotic Drugs, Psychotropic Substances and Precursors. zakon.rada.gov.ua (n.d.). https://zakon.rada.gov.ua/laws/show/770-2000-%D0%BF#Text1
- Misuse of Drugs Act 1971, Schedule 2, Part II, paragraph 1(aa). legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/1971/38/schedule/21
Further Reading
EMCDDA: Initial Report on 3-CMC (2022)
EMCDDA: Risk Assessment Report on 3-CMC (2021)
Metabolism of 3-CMC in human dried blood spots (2024)
Synthetic Cathinones and Neurotoxicity Risks: A Systematic Review (DOI)
Walther et al. 2019 - Structure-Activity Studies on Methcathinones (DOI)
WHO 46th ECDD Critical Review: 3-CMC (2024)
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 3-CMC article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.